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What is already known on this subject?
• Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with limited therapeutic options.
• Pancreatic cancer stem cells (CSCs) are exclusively tumourigenic and highly resistant to chemotherapy.
• Tumour-associated macrophages are important for the progression and metastatic spread of many solid tumours.
What are the new findings?
• The immuno-modulatory cationic antimicrobial peptide 18/leucine leucine-37 (hCAP-18/LL-37) is over expressed in the stroma of PDAC and acts on CSCs to potentiate their inherent biological properties.
• Tumour-associated macrophages secrete hCAP-18/LL-37 in direct response to CSC-secreted NODAL/ACTIVINA/TGF-β1.
• Small molecule targeting of the LL-37 receptors formyl peptide receptor 2 (FPR2) and P2X purinoceptor 7 receptor (P2X7R), present on pancreatic CSCs, negatively impacts tumour growth and circulating tumour cell numbers.
How might it impact on clinical practice in the foreseeable future?
• The discovery of the crucial role of hCAP-18/LL-37 in cancer stem cell biology represents an important advancement in our understanding of the PDAC tumour microenvironment.
• Targeting pancreatic CSCs using inhibitors of the LL-37 receptors FPR2 and P2X7R may represent a specific therapeutic approach to block the tumour promoting cross-talk that exists within the tumour microenvironment. 
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers largely due to its high resistance to current treatment strategies [1] . This can at least, in part, be attributed to a subpopulation of cells known as pancreatic cancer stem cells (CSCs) [2, 3, 4] , which are defined by their cell-intrinsic and unlimited self-renewal, exclusive long-term tumourigenicity, capacity to recapitulate the entire cancer cell heterogeneity, and metastatic potential [5, 6, 7] . In addition, PDAC is characterized by extensive desmoplasia [8] , which is made up of heterogeneous cell populations, including pancreatic stellate cells (PSCs) [9, 10] and immune cells [8, 11, 12, 13, 14, 15] . This dynamic cellular microenvironment may directly or indirectly promote CSCs features [6, 10, 16, 17] , but few comprehensive studies have been performed in PDAC to date. Thus, we set out to identify stroma-specific paracrine drivers that potentiate pancreatic CSC features.
Here we show that the human cationic anti-microbial protein 18 (hCAP-18, CAMP), the only known human cathelicidin alarmin [18, 19, 20] , is strongly and exclusively expressed by macrophages present within the PDAC stroma. Cleavage of hCAP-18 at the COOH-terminal end gives rise to the biologically active 37 amino acid hCAP-18 peptide called leucine leucine-37 (LL-37) [19, 20] .
Intriguingly, secreted LL-37, via the G protein-coupled receptor, formyl peptide receptor 2 (FPR2) [21, 22, 23] and P2X(7) purinergic receptor [22] , significantly potentiated pancreatic CSC features, such as self-renewal, invasion and tumourigenesis. While the factors that mediate LL-37 expression can vary based on the biological context, we also show for the first time that CSC-secreted TGF-β family members and subsequently cultured in vitro as previously detailed [7] . Human blood was obtained from healthy donors with informed consent. Monocyte-derived human macrophage cultures were established and polarized to an M1 phenotype with GM-CSF as previously described [24, 25, 26] . (Fig. 1A) . Interestingly, at 1.5 weeks human macrophages were no longer detected in these tumours as determined by a lack of CD68, CD16 and CD163 staining (data not shown), suggesting that the transient presence of human macrophages was sufficient to jumpstart tumour take and promote PDAC cell growth in vivo.
To begin to understand how macrophages might promote PDAC tumour growth, we co-cultured human monocyte-derived unpolarized macrophages with and without primary PDAC cells in trans-wells (to separate the two cell types) and performed microarray analyses (Table S1 ). Of the top 25-up-regulated genes in macrophages (FDR<10 -4 , logFC>2), 19 genes belonged to the family of interferon-stimulated genes ( Fig. 1B) , while the 6 remaining genes (RSAD2, CMPK2, KRT19, CAMP, SIGLEC1, and ORM1) encoded for proteins with diverse functions. We identified hCAP-18/LL-37 (ie, CAMP) as a gene of interest as it both encodes for a secreted factor and has been shown to be expressed in other solid tumours, including breast [29, 30] , lung [31, 32, 33] and ovarian cancers [18, 23, 34] , albeit in the epithelial compartment. RT-qPCR analysis (Fig. 1C) and immunofluorescence confocal microscopy ( Fig. 1D) showed up-regulation of hCAP-18/LL-37 in monocyte-derived unpolarized macrophages only when cocultured with primary PDAC cells, validating our microarray results. Moreover, while PDAC cells cocultured with macrophages did not express hCAP18/LL-37 (data not shown), we observed up-regulation of pluripotency-associated genes, which was blocked by the addition of LL-37 blocking antibodies or inhibitors, suggesting an LL-37-mediated cross talk between macrophages and CSCs ( Fig. 1E and S1 ). Fig. 2A and S2A) . Interestingly, only the stroma stained positive for hCAP18/LL-37 while cancer cells were negative ( Fig. 2A and S2A-C ;PDX-1-Cre (hereafter referred to as KPC) [27] mouse model of PDAC.
CRAMP (ie, murine homolog of hCAP-18/LL-37) expression in KPC mice was similarly restricted to the tumour stroma, absent in normal tissue, and most prominently expressed in primary PDAC lesions and in all metastatic lesions of secondary organs, such as the liver ( Fig. 2E and S4A) . Staining for the macrophage markers YM1 or F4/80 also revealed a strong correlation between macrophages and CRAMP staining (Fig. 2E, S4B-C (Fig. 3C, right) . In addition, we found a clear reduction in the percentage of CD133+ cells in the tumour formed in the CRAMP -/-mouse (Fig. 3D) . To further dissect these phenotypes at the macrophage level, we injected 5×10 5 primary sphere-derived CSC-enriched murine PDAC cells alone or with equal numbers of monocyte-derived unpolarized macrophages isolated from wild-type or CRAMP -/-mice.
After 4 weeks, tumour take and growth was significantly accelerated when murine PDAC cells were coinjected with wild-type macrophages [similar to what was observed when human macrophages were coinjected with human PDAC cells (Fig. 1A) ], but not with CRAMP -/-macrophages (Fig. 3E) . In line with these observations, murine PDAC sphere formation was consistently enhanced in the presence of wildtype macrophages versus CRAMP -/-macrophages ( Fig. S5D) , suggesting that CRAMP enhances/promotes PDAC tumour take and progression by potentiating CSC in vivo self-renewal and tumourigenesis.
hCAP18/LL-37 has inherent pro-CSC properties. Stimulated by these proof-of-concept studies,
we next aimed to further dissect the mechanisms of action for LL-37 on human pancreatic cancer (stem) cells. Using the established CSC cell surface marker CD133 [2] and a novel biomarker for CSC, and S6A) and autofluorescent populations ( Fig. 4B and S6A) , suggesting that LL-37 increases the CSC pool. Indeed, colony-forming (Fig. 4C) , and sphere-forming efficiency (Fig. 4D) were both significantly enhanced by rLL-37; the latter even more pronounced during serial passaging, which further enriches for CSCs (Fig. 4D) . Treatment also resulted in over expression of KLF4, SOX2, OCT3/4, and NANOG in rLL-37-treated spheres ( Fig. 4E and S6B-C) . Of note, recombinant CRAMP functioned similarly to rLL-37 in CSCs derived from KPC mouse pancreatic tumours (Fig. S7) . Lastly and in line with a pro-CSC effect, rLL-37 also increased the inherent chemoresistant potential of CSCs, as measured by increased CD133+ cells following treatment with Gemcitabine or Abraxane ( Fig. 4F and S8) .
Importantly, the most defining feature of CSCs lies in their ability to form tumours in vivo.
Sphere-derived PDAC cells pre-treated with rLL-37 revealed consistently enhanced tumourigenicity, a higher CSC frequency, and increased early tumour take as compared to scrambled peptide-treated cells.
Notably, this effect was particularly evident when low cell numbers (~10 cells) were injected ( Fig. 5A-B ).
In line with our hypothesis that the effects of LL-37 are preferentially affecting CSCs, when we injected adherent cells, which contain few CSCs [6] , the differences in tumourigenicity between non-treated and 
LL-37 promotes CSC invasiveness.
We found the highest expression of LL-37 and CRAMP in primary PDAC tumours and metastatic lesions of human and mouse origins ( Fig. 2) , respectively, suggesting that LL-37 is likely important late during PDAC progression and may be involved in EMT.
Supporting this hypothesis, rLL-37 treatment increased the CXCR4+ subpopulation ( Fig. 6A ) present in CSCs, a subpopulation of CSCs that drives metastasis [2] . Analysis of EMT-related genes following rLL-37 treatment revealed down-regulation of E-cadherin and up-regulation of Vimentin and Snail ( Fig macrophage markers CD163, CD204 and CD206 [37, 38, 39] (Fig. S11) .
TGF-β can polarize 'M1' macrophages to an 'M2'/alternatively activated phenotype [40] and cancer cells, including PDAC cells do secrete large amounts of TGF-β ( Fig. S12A ) [41] . As many advanced PDAC tumours harbor inactivating mutations in the TGF-β signaling pathway rendering them unresponsive [42] , we reasoned that TGF-β secreted by PDAC cells may instead primarily act on macrophages inducing LL-37 expression. In addition, we recently showed that PDAC CSC over express other member of the TGF-β superfamily, namely Nodal/ActivinA [6] , which may also be implicated in the macrophage-CSC-crosstalk. Indeed, pre-treatment of M1-polarized GM-CSF-treated monocyte-derived human macrophages with the TGFβ family members Nodal/ActivinA or TGF-β significantly increased S12B-C), the latter three of which have been shown to regulate hCAP18/LL-37 expression. Blocking
Nodal/ActivinA/TGF-β signaling in CSC CM-treated macrophages with SB431542 and SB505124, both of which are inhibitors of the respective receptors Activin-like 4 (Alk4) and Alk5, abolished the enhanced expression of LL-37 and additional target genes (Fig. 7H) .
Targeting LL-37 signaling impairs CSC tumourigenesis. hCAP-18/LL-37 is believed to exert its effects through the receptors FPR2 [21, 22] and/or P2X7R [22, 43] (Fig. 8A) , both of which were detectable at the mRNA level and by flow cytometry in several primary PDAC cultures ( which increased when cells were cultured as spheres (2-5%) and treated with rLL-37 (4-8%). More importantly, the expression of both receptors was primarily (>60%) restricted to CD133+ cells ( Fig. 8C and Fig. S13A ). The latter was particularly evident in a freshly digested PDAC patient tumour (Fig.   S13B ). These data together suggest an enrichment of these receptors in CSCs. Using inhibitors specific for both FPR2 and P2X7R (WR-W4 and KN-62, respectively), LL-37-induced colony formation ( Fig.   8D) , invasion ( Fig. 8E ) and CD133+ cell expansion (Fig. 8F) was reduced with each inhibitor alone or in combination, confirming that the effects of LL-37 are indeed mediated through these receptors.
To rigorously test the therapeutic potential of anti-LL-37 therapy in vivo, we treated KPC or KPCR (KPC mice that additionally express a pancreas-specific RFP reporter) mice with WR-W4 and KN-62 for either 5 weeks (short-term) or 16 weeks (long-term) (Fig. 9A) . With as little as 5 weeks of treatment, there was a marked reduction in the number of RFP+ circulating tumour cell of KPCR mice (Fig. 9B) . In addition, we observed reduced numbers of low-grade PanINs and significantly fewer highgrade PanINs and PDAC lesions (Fig. 9C ) in treated mice. Of note, no liver metastases were detected in either group at this stage. By extending our treatment to 16 weeks, the number of CTCs (EPCAM+) in treated mice were still reduced (Fig. 9D) . With respect to the pancreas, while no impact on the incidence of low-grade PanINs was observed, we still quantified significantly fewer high-grade PanINs and PDAC 
CONCLUSION / DISCUSSION
While the PDAC tumour microenvironment is composed of many different cells, TAMs are likely one of the most dynamic resident cells of the tumour stroma [12, 13, 14, 16, 17, 39, 44, 45] . Not only can they enhance tumour growth when co-injected in vivo, but our microarray analyses additionally showed that monocyte-derived human macrophages are transcriptionally re-programmed by PDAC cells. For example, macrophages up-regulated a large number of genes belonging to the family of interferonstimulated genes (OAS, MX1, ISG15, etc.), which we hypothesize is due to IFN-β produced by PDAC cells [46] , similar to what has been shown for other Kras-transformed tumours [47] . Macrophages also down-regulated the expression of chemokines and pro-inflammatory genes, such as CXCL1, CXCL2, IL-1 and IL-6, as well as macrophage M1 markers, such as CD68, thus providing a first indication that PDAC cells alter the differentiation/polarization state of macrophages. Most intriguingly, however, macrophages also up-regulated the expression of hCAP18/LL-37, a peptide previously reported to be either pro-or anti-tumourigenic in other cancer models [18, 29, 48, 49] , but had not yet been studied in the context of pancreatic CSC to date and revealed several interesting and novel findings.
The antimicrobial peptide hCAP18/LL-37 was detectable across a large set of PDAC tumours at both the mRNA and protein level, and its expression was most prominent in PDAC and secondary metastatic lesions. hCAP18/LL-37 was originally identified as a host immune anti-microbial defensin molecule and is constitutively secreted by a variety of immune cells (eg, neutrophils and macrophages), but can also be expressed by epithelial cells and fibroblasts [50] . Interestingly, human and murine PDAC epithelial cells were univocally negative for hCAP18/LL-37 or CRAMP, respectively, although previous
studies examining breast, lung, and ovarian cancers had shown that hCAP18/LL-37 is expressed by the tumour epithelium [18, 29] . Instead, in PDAC, expression of hCAP18/LL-37 was clearly restricted to the tumour stroma, revealing a previously unappreciated and important difference between tumour entities with respect to the source of hCAP18/LL-37 expression. We predict that PDAC cells may be deficient in certain signaling factors that are necessary for hCAP18/LL-37 expression, such as vitamin D activated
PPARγ signaling [51] , NF-κB-mediated CCAAT/enhancer-binding protein α (C/EBP) activation via MAPK-mediated phosphorylation [52] , or other yet unidentified pathways. Within the tumour stroma, we identified macrophages as the primary source of LL-37; however, polymorphonuclear neutrophils can also secrete LL-37 [50] and have been shown to be one of the many types of tumour infiltrating cells detected in pancreatic neoplasias [53] . Thus, while we focused on TAMs, we note that other immune infiltrating cells likely also produce LL-37 in vivo.
LL-37 has been shown to signal through P2X7R and FPR2 [21, 22, 23] , both of which were detectable on the surface of PDAC cells, and their expression were primarily restricted to CSCs (ie, CD133+ cells). As CSCs are the driving subpopulation of cells in PDAC with exclusive tumourigenic potential, and since tumour take and growth was significantly increased when PDAC cells were coinjected with macrophages, we thus reasoned that macrophages potentiate tumour growth via an LL-37-mediated pro-CSC mechanism. We confirmed this hypothesis in vivo by using CRAMP knockout mice as a source of bone marrow for transplantation experiments in irradiated KPC mice, as a syngeneic model to study CSC-mediated tumour take and growth or as a source of monocyte-derived macrophages for coinjection tumourigenicity studies with murine PDAC CSCs. All three approaches conclusively demonstrated that CRAMP is necessary for CSC-mediated PDAC development and progression in vivo.
Importantly, these results are in agreement with those published by Li et al., where they show that cathelicidin (ie, CRAMP) expressed from murine myeloid cells promotes cigarette smoke-induced lung tumour growth in vivo [32, 33] .
To validate the biological relevance of our in vivo findings in the human setting, we showed that rLL-37 increased the CSC pool using two independent markers for CSCs (ie, CD133 and enhances the responsiveness of hematopoietic stem progenitor cells to an SDF-1 gradient by CXCR4 cell surface stabilization [55] . In line with these findings, we observed a 3-fold increase in CXCR4 cell membrane expression in rLL-37-treated cells, indicating that LL-37 likely primes CSCs for the SDF-1/CXCR4 axis via a similar CXCR4-dependent mechanism.
Members of the TGF-β superfamily, namely Bone Morphogenic Proteins, TGF-β, and
Nodal/ActivinA, exert multiple and sometimes opposing effects on a variety of cell types. We have [33, 56] and hCAP/LL-37 expression has also been shown to be regulated by NFkB phospho-p50 and phospho-p38 [52] . In macrophages treated with CSC-conditioned media or TGF-β, Nodal and ActivinA, NFkB phospho-p50 and phospho-p38 activation was observed as well as transcriptional upregulation of VDR, implicating these factors as common mediators by which TGF-β superfamily members regulate LL-37 expression and thus promote formation of a pro-CSC niche.
Targeting the tumour microenvironment has gained enormous attention over the past decade, particularly the development of agents that can disrupt the crosstalk between cancer cells and the stroma.
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